Understanding the 2026 Dyslipidemia Guidelines: New Risk Tools for Management

The release of the 2026 ACC/AHA Dyslipidemia Guideline marks the most comprehensive update to cardiovascular risk and lipid management guidance in nearly a decade, introducing new risk estimation tools, expanded treatment thresholds, and a broadened scope now encompassing all atherogenic lipoproteins.

In this opening segment of HCPLive's Special Report series, Pamela B. Morris, MD, vice chair of the 2026 guideline writing committee, is joined by fellow committee member Ann Marie Navar, MD, PhD, a cardiovascular disease prevention specialist at UT Southwestern Medical Center.

Together, Morris and Navar outline the foundational changes clinicians must understand before applying the updated recommendations in practice.

Central to this update is the replacement of the Pooled Cohort Equations with the AHA PREVENT equations for cardiovascular risk estimation. The PREVENT equations address well-documented limitations of the prior model, which was known to overestimate 10-year atherosclerotic cardiovascular disease (ASCVD) risk by approximately twofold.

The new equations incorporate a broader range of risk factors, extend estimation to adults as young as age 30, and provide 30-year risk projections for patients up to age 59, a clinically meaningful addition for long-term prevention planning.

With this transition comes a recalibration of risk thresholds. Under PREVENT, a 10-year ASCVD risk below 3% is classified as low; 3% to 5% as borderline; 5% to 10% as intermediate; and above 10% as high. Navar emphasizes these revised categories are not arbitrary—they reflect more accurate absolute risk estimates.

For patients in the borderline-to-intermediate range, clinicians are directed to consider additional risk stratification tools, including coronary artery calcium (CAC) scoring and an expanded set of risk-enhancing factors. Statin therapy is now recommended for patients with LDL cholesterol of 160 mg/dL or higher, even in the setting of low 10-year risk, to account for cumulative lifetime exposure. The lower age threshold for risk assessment is driven entirely by the expanded predictive capacity of PREVENT rather than any arbitrary push toward earlier treatment.

Morris has no relevant disclosures to report. Navar reports disclosures with Amge, Arrowhead Pharmaceuticals, AstraZeneca, Bayer, Eli Lilly and Company, Esperion, Johnson & Johnson, Merck, Miga Health, NewAmsterdam Pharma, Novartis, Novo Nordisk, Sanofi, and Silence Therapeutics, among others.

References:

1. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. Published online March 13, 2026. doi:10.1016/j.jacc.2025.11.016
2. American College of Cardiology. ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol - American College of Cardiology. American College of Cardiology. Published March 13, 2026. Accessed March 23, 2026. https://www.acc.org/About-ACC/Press-Releases/2026/03/13/18/01/ACCAHA-Issue-Updated-Guideline-for-Managing-Lipids-Cholesterol